TWI632236B - Lactobacillus gasseri br-0121 and use thereof - Google Patents

Abstract

A Lactobacillus bergii BR-0121 has the activity of reducing the residual of heavy metal lead in the body. The Lactobacillus berghei BR-0121 is deposited in the Republic of China Food Industry Development Institute, and its registration number is BCRC 910770. The invention further relates to the use of the Lactobacillus bulgaricus BR-0121.

Description

Lactobacillus kawaii BR-0121 and its use

The present invention relates to a lactobacillus, and more particularly to a Lactobacillus gasseri BR-0121. The invention further relates to the use of the Lactobacillus bulgaricus BR-0121.

Lead is a highly toxic metal that not only causes serious damage to the brain and kidneys, but may even cause death. It can usually pass through heavy metal binders such as dimercaprol and succimer. The drug is administered to chelate heavy metal lead and form a complex that can be excreted from the body, thereby reducing the residual of heavy metal lead in the body; however, dimercaptopropanol causes an increase in the concentration of cadmium in the kidney, and increases the toxicity of selenium and tellurium; While succinic acid can cause skin mucosal lesions and nausea and vomiting, it is still necessary to provide a drug that reduces the residual of heavy metal lead in the body.

In order to solve the above problems, the present invention provides a Lactobacillus bergii BR-0121 which has an activity of lowering the residual of heavy metal lead in the body.

The invention further provides a use of Lactobacillus gasseri BR-0121 for preparing a medicament for reducing the residue of heavy metal lead in the body.

The Lactobacillus gasseri BR-0121 of the present invention is deposited in the Republic of China Food Industry Development Research Institute, and its registration number is BCRC 910770; the Lactobacillus bergii BR-0121 has the activity of reducing the residual of heavy metal lead in the body, which is the present invention. The effect.

The use of Lactobacillus gasseri BR-0121 of the present invention is for preparing a reduced body A drug containing residual metal lead, wherein the Lactobacillus bergii BR-0121 is deposited in the Republic of China Food Industry Development Research Institute under the registration number BCRC 910770; thus the biological activity of the Lactobacillus bulgaricus BR-0121 It can effectively combine the heavy metal lead in the body of the desired individual, thereby achieving the effect of reducing the residual of heavy metal lead in the body, and is the effect of the invention.

The use of the Lactobacillus gasseri BR-0121 of the present invention, wherein the Lactobacillus bergii BR-0121 is administered to a desired individual to reduce the residual of heavy metal lead in the body of the desired individual; the Lactobacillus bergii BR -0121 is administered orally to the desired individual, and the Lactobacillus bergii BR-0121 is capable of administering a dose of 7×10 ⁸ to 9×10 ⁸ CFU per body weight of the desired individual per day. Preferably, the desired individual can be administered to the individual in need of a dose of 8 x 10 ⁸ CFU per kilogram of the desired individual per day; thus, the dosage of the Lactobacillus bulgaricus BR-0121 is administered. Therefore, the Lactobacillus gasseri BR-0121 can more effectively reduce the residual of heavy metal lead in the body.

Figure 1: Bar graph of percent change in lead content in hair of each group of subjects in this trial.

The above and other objects, features and advantages of the present invention will become more <RTIgt; ( Lactobacillus gasseri ) BR-0121 is screened from the neonatal intestine, which is deposited in the Republic of China Food Industry Development Institute (Accession No. BCRC 910770) and has a 16S rDNA sequence as shown in SEQ ID NO: 1. Lactobacillus gasseri BR-0121 can effectively bind heavy metal lead in a desired individual, and thus can be applied to prepare a medicine, a health food or a nutritional supplement which reduces the residual of heavy metal lead in the body. For example, the Lactobacillus bergii BR-0121 can be administered to a desired individual at a dose of 7 x 10 ⁸ to 9 x 10 ⁸ CFU per kg of the desired individual per day, preferably daily. A dose of 8 x 10 ⁸ CFU per kg of the desired individual is administered to the desired individual, thereby effectively reducing the residual of heavy metal lead in the body of the desired individual.

Further, the Lactobacillus bergii BR-0121 can also be combined with a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, wherein the Lactobacillus bergii BR-0121 can be prepared for any convenient consumption. The form, such as a tablet, a capsule, a powder, a granule or a liquid, or the like, or the combination of the Lactobacillus gasseri BR-0121 with other foods or beverages, is suitable for consumption in an edible form for the organism to be taken orally.

In order to confirm that the Lactobacillus gasseri BR-0121 can effectively reduce the residual of heavy metal lead in the body of the desired individual, the following test is carried out: the test is performed by the subject to orally use the Lactobacillus kawaii BR-0121 every day. (Group A1), Lactobacillus paracasei (Group A2), Lactobacillus reuteri (Group A3), Lactobacillus acidophilus (Group A4) or Bifidobacterium Longum , group A5), after 180 days, the lead content in the hair of each subject was measured, and the percentage change of lead content in each group of hair was calculated.

Referring to Fig. 1, the amount of lead in the hair of the A2~A5 group of the Lactobacillus species which is orally administered orally every day is used daily, and the number of the Lactobacillus bulgaricus BR-0121 is orally administered daily. The lead content in the hair of the A1 group was significantly decreased (the percentage change was about 50%), indicating that the Lactobacillus berghei BR-0121 did have an effect of lowering the residual of heavy metal lead in the body than the Lactobacillus species.

In summary, the Lactobacillus gasseri BR-0121 of the present invention has an activity of lowering the residual of heavy metal lead in the body, and is an effect of the present invention.

Furthermore, the use of the Lactobacillus kawaii BR-0121 of the present invention is for preparing a medicament for reducing the residual of heavy metal lead in the body, so that the biological activity of the Lactobacillus kawaii BR-0121 can effectively bind the desired individual. Heavy metal lead in the body, which in turn reduces heavy metals in the body The effect of residual lead is the efficacy of the present invention.

While the invention has been described in connection with the preferred embodiments described above, it is not intended to limit the scope of the invention. The technical scope of the invention is protected, and therefore the scope of the invention is defined by the scope of the appended claims.

【Biomaterial Storage】 Domestic registration information [please note according to the registration authority, date, number order]

Republic of China Food Industry Development Institute, February 14, 2017, BCRC 910770

Foreign deposit information [please note according to the country, organization, date, number order]

(no)

<110> Guangsheng Biotechnology Co., Ltd.

<120> Lactobacillus kawaii BR-0121 and its use

<130> PK14889

<160> 1

<170> PatentIn version 3.5

<210> 1

<211> 1464

<212> DNA

<213> Lactobacillus gasseri

<400> 1

Claims (6)

A Lactobacillus kawaii BR-0121, deposited in the Republic of China Food Industry Development Institute, has a registration number BCRC 910770. The use of a Lactobacillus kawaii BR-0121 for the preparation of a medicament for reducing the residue of heavy metal lead in the body, wherein the Lactobacillus bergii BR-0121 is deposited in the Republic of China Food Industry Development Institute, and its registration number is BCRC. 910770. The use of the Lactobacillus gasseri BR-0121 according to claim 2, wherein the Lactobacillus bergii BR-0121 is administered to a desired individual to reduce the residual of heavy metal lead in the body of the desired individual. . The use of Lactobacillus gasseri BR-0121 according to claim 3, wherein the Lactobacillus bergii BR-0121 is administered orally to the desired individual. The use of Lactobacillus gasseri BR-0121 according to claim 4, wherein the Lactobacillus bergii BR-0121 is administered at a dose of 7×10 ⁸ to 9× per kg of body weight per day. A dose of 10 ⁸ CFU is administered to the desired individual. The use of Lactobacillus gasseri BR-0121 according to claim 5, wherein the Lactobacillus bergii BR-0121 is administered at a dose of 8 × 10 ⁸ CFU per kg of the body weight of the individual required per day. The desired individual is administered.